MRI-guided thrombolysis for lenticulostriate artery stroke within 12 h of symptom onset.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
06 05 2022
06 05 2022
Historique:
received:
25
08
2021
accepted:
01
04
2022
entrez:
6
5
2022
pubmed:
7
5
2022
medline:
11
5
2022
Statut:
epublish
Résumé
Stroke thrombolysis treatment is generally administered within 4.5 h, but a greater time window may be permitted depending upon the ischemic penumbra on neuroimaging. This observational cohort study investigated the outcomes of thrombolysis given within 12 h after symptom onset of lenticulostriate artery stroke. The population comprised 160 patients. Thrombolysis was administered via tissue plasminogen activator, alteplase (TPA). Thrombolysis was indicated by a mismatch between diffusion-weighted imaging (DWI) and T2-weighted imaging (T2WI), that is, an acute ischemic lesion on DWI without a corresponding lesion on T2WI. Demographics and medical history were compared with the modified Rankin scale (mRS) score, to reflect outcome. Patients with a favorable clinical outcome (mRS 0-1) had significantly lower hypertension, baseline NIH Stroke Scale (NIHSS) score, and admission systolic/diastolic blood pressure compared with patients with mRS 2-6. Lower admission systolic blood pressure and NIHSS score were significantly associated with favorable outcome. In patients either with IV-TPA within 4.5 h, or between 4.5 and 12 h, lower admission systolic blood pressure and/or NIHSS score similarly independently predict favorable outcome. However, in all groups, the onset-to-treatment time did not significantly influence the outcomes. We conclude that in our cohort higher admission systolic blood pressure and higher baseline NIHSS and not time were associated with poor outcome in patients with magnetic resonance-guided thrombolysis within 12 h of isolated lenticulostriate artery stroke, therefore loosening the traditionally perceived dependency of outcome on time.
Identifiants
pubmed: 35523924
doi: 10.1038/s41598-022-11459-3
pii: 10.1038/s41598-022-11459-3
pmc: PMC9076823
doi:
Substances chimiques
Fibrinolytic Agents
0
Tissue Plasminogen Activator
EC 3.4.21.68
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7445Informations de copyright
© 2022. The Author(s).
Références
J Neurol. 2017 Jul;264(7):1381-1387
pubmed: 28597318
Stroke Vasc Neurol. 2019 Feb 11;4(1):8-13
pubmed: 31105973
Hypertension. 2009 Nov;54(5):1050-6
pubmed: 19805635
Hypertension. 2000 Sep;36(3):312-8
pubmed: 10988257
AJR Am J Roentgenol. 2016 Feb;206(2):395-400
pubmed: 26797370
Angiogenesis. 2015 Jul;18(3):265-81
pubmed: 25862671
Stroke. 2018 Mar;49(3):e46-e110
pubmed: 29367334
Neurology. 1989 Apr;39(4):507-12
pubmed: 2927674
Int J Stroke. 2021 Dec;16(9):1039-1046
pubmed: 31955704
Hypertension. 2019 Jan;73(1):197-205
pubmed: 30571554
Circulation. 2008 Jul 8;118(2):176-87
pubmed: 18606927
AJNR Am J Neuroradiol. 2010 Jun;31(6):1015-22
pubmed: 20190209
Cerebrovasc Dis. 2000 Jul-Aug;10(4):261-71
pubmed: 10878430
J Stroke Cerebrovasc Dis. 2014 Apr;23(4):e263-9
pubmed: 24468070
N Engl J Med. 2018 Aug 16;379(7):611-622
pubmed: 29766770
Stroke. 2008 Feb;39(2):366-72
pubmed: 18096843
JAMA Neurol. 2019 Jun 1;76(6):641-649
pubmed: 30907934
Neuroradiology. 1997 Jun;39(6):406-10
pubmed: 9225318
Ann Neurol. 2018 May;83(5):980-993
pubmed: 29689135
Neurol Res. 2008 May;30(4):344-7
pubmed: 18544249
J Neurol. 2019 Feb;266(2):283-288
pubmed: 29922951
Stroke. 2018 Nov;49(11):2605-2611
pubmed: 30355198
Neurol Res. 2013 Jun;35(5):492-7
pubmed: 23601825
Hypertension. 2007 Jul;50(1):204-11
pubmed: 17470716
N Engl J Med. 2008 Sep 25;359(13):1317-29
pubmed: 18815396